Skip to content
Medx

Tag: Luxturna

Explore our medication guides and pharmacology articles within this category.

Luxturna: What was the first AAV gene therapy approved by the FDA?

•
4 min read
On December 19, 2017, the FDA approved Luxturna, making history as the first AAV gene therapy for a genetic disease in the U.S.. The therapy, developed by Spark Therapeutics, provides a functional gene to treat inherited retinal dystrophy caused by biallelic mutations in the *RPE65* gene.

What Is the Most Expensive Eye Drug?

•
2 min read
Costing $425,000 per eye, Luxturna (voretigene neparvovec-rzyl) is a one-time gene therapy widely recognized as the most expensive eye drug. This revolutionary treatment targets a rare, inherited form of vision loss and represents a significant advancement in the field of ophthalmic medicine.